EGFR and non-small cell lung carcinoma: Clinical trials have tested the efficacy of dasatinib in NSCLC as a single agent [6], in combination with currently used chemotherapy regimens such as the epidermal growth factor receptor (EGFR) inhibitor erlotinib [7], and in patients who have developed resistance to erlotinib and gefitinib [8].